Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.29 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management emphasized the importance of ongoing clinical trials. They did not offer specific guidance for future performance.
Management did not provide specific guidance for future quarters.
The focus remains on advancing clinical programs.
Protagonist Therapeutics reported a loss per share of $0.29, which was in line with expectations, but no revenue figures were disclosed. The stock reacted positively, increasing by 0.27%. This slight uptick may reflect investor confidence in the company's ongoing clinical programs despite the lack of specific guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMEREN CORP
Nov 3, 2017